journal article·2026-06

ALP‐Responsive Luminescent Nanosheets Promote Precise Hepatitis Theragnostic by Co‐Targeting NLRP3 and Cholestasis

Jieying Qian, Zhixin Wu, Xianwu Yan, Zhenyu Yang, Yaoxu Chen, Youpei Zhang, Sitong Du, Tianyi Jiang, Yuping Zhou, Qingqi Zheng, Xiaowan Huang, Hao Zhang, Yunjiao Zhang

Advanced Materials· Volume 38· Issue 33
Publisher page

Abstract

ABSTRACT Cholestatic hepatitis is a progressive inflammatory liver disease characterized by disrupted bile acid homeostasis, excessive reactive oxygen species (ROS) generation, and chronic inflammation, remains clinically challenging due to limited diagnostic precision and lack of effective, targeted therapies. Here, we developed a multifunctional theranostic nanoplatform, CyP‐CuGA‐UDCA nanosheets (NSs), that integrates therapeutic intervention with enzyme‐responsive disease monitoring. The platform features copper‐gallic acid (CuGA) nanozymes with superoxide dismutase‐, peroxidase‐, and catalase‐like activities for effective ROS scavenging and NLRP3 inflammasome inhibition. Co‐loaded with ursodeoxycholic acid (UDCA) to alleviate bile acid toxicity, and with an alkaline phosphatase (ALP)‐responsive near‐infrared fluorescent probe (CyP), the nanoplatform enables targeted treatment and real‐time imaging of cholestatic lesions. In a DDC‐induced mice model, CyP‐CuGA‐UDCA NSs significantly suppressed pro‐inflammatory cytokine production, reduced hepatic macrophage infiltration, attenuated oxidative stress and hepatocyte apoptosis, and alleviated fibrosis, outperforming monotherapies. Concurrently, the ALP‐activated fluorescence allowed precise visualization of cholestatic progression in vivo. This study presents a first‐in‐class nanostructured system that couples NLRP3 inflammasome modulation and bile acid regulation with enzyme‐specific diagnostics, offering a robust strategy for precision therapy and monitoring of cholestatic hepatitis.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Advanced Nanomaterials in Catalysis · Nanoplatforms for cancer theranostics · Sulfur Compounds in Biology

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

School of Medicine South China University of Technology Guangzhou Guangdong P. R. China

National Engineering Research Center for Tissue Restoration and Reconstruction, Key Laboratory of Biomedical Engineering of Guangdong Province South China University of Technology Guangzhou Guangdong P. R. China

Funding

National Key Research and Development Program of China · National Natural Science Foundation of China · Fundamental Research Funds for the Central Universities

References (40)

Show source-provided references
1. 10.1038/s41575‐019‐0226‐710.1038/s41575‐019‐0226‐7 ↗
2. Current Therapeutics in Primary Sclerosing Cholangitis
3. 10.1016/j.jhep.2008.08.01310.1016/j.jhep.2008.08.013 ↗
4. 10.1186/s12929‐024‐01052‐310.1186/s12929‐024‐01052‐3 ↗
5. 10.1016/S0140‐6736(18)30300‐310.1016/S0140‐6736(18)30300‐3 ↗
6. 10.3390/cells1010261810.3390/cells10102618 ↗
7. 10.1152/ajpheart.01182.200510.1152/ajpheart.01182.2005 ↗
8. 10.3727/105221619X1561487306273010.3727/105221619X15614873062730 ↗
9. 10.1016/j.cell.2010.01.04010.1016/j.cell.2010.01.040 ↗
10. 10.1038/nm.389310.1038/nm.3893 ↗
11. 10.1038/s41577‐019‐0165‐010.1038/s41577‐019‐0165‐0 ↗
12. 10.1038/nm.380610.1038/nm.3806 ↗
13. 10.1038/nrd.2018.9710.1038/nrd.2018.97 ↗
14. Alkaline Phosphatase Normalization Is a Biomarker of Improved Survival in Primary Sclerosing Cholangitis
15. 10.1016/j.trac.2023.11733510.1016/j.trac.2023.117335 ↗
16. 10.1002/anie.20231403910.1002/anie.202314039 ↗
17. 10.1021/jacs.4c0073110.1021/jacs.4c00731 ↗
18. 10.1016/j.talanta.2024.12647510.1016/j.talanta.2024.126475 ↗
19. 10.1038/s41467‐023‐36469‐110.1038/s41467‐023‐36469‐1 ↗
20. 10.1002/anie.20200167510.1002/anie.202001675 ↗
21. 10.1002/adhm.20230134610.1002/adhm.202301346 ↗
22. 10.1146/annurev‐biochem‐061516‐04503710.1146/annurev‐biochem‐061516‐045037 ↗
23. 10.1002/adfm.20221469310.1002/adfm.202214693 ↗
24. 10.1038/s41467‐020‐16544‐710.1038/s41467‐020‐16544‐7 ↗
25. 10.1021/jacs.5b1207010.1021/jacs.5b12070 ↗
26. 10.1021/cr500310b10.1021/cr500310b ↗
27. 10.1002/anie.20240593710.1002/anie.202405937 ↗
28. 10.1007/s00109‐020‐02032‐410.1007/s00109‐020‐02032‐4 ↗
29. 10.1016/j.jcmgh.2019.12.00810.1016/j.jcmgh.2019.12.008 ↗
30. 10.1038/nri.2016.5810.1038/nri.2016.58 ↗
31. 10.1002/mco2.10410.1002/mco2.104 ↗
32. 10.1016/j.atherosclerosis.2017.10.02710.1016/j.atherosclerosis.2017.10.027 ↗
33. 10.1016/j.cell.2015.12.05710.1016/j.cell.2015.12.057 ↗
34. 10.1074/jbc.M60808320010.1074/jbc.M608083200 ↗
35. 10.1159/00048508910.1159/000485089 ↗
36. 10.1038/ni.183110.1038/ni.1831 ↗
37. 10.1084/jem.182.2.36710.1084/jem.182.2.367 ↗
38. 10.1517/14728222.2016.110373510.1517/14728222.2016.1103735 ↗
39. 10.1038/s41467‐022‐32575‐810.1038/s41467‐022‐32575‐8 ↗
40. 10.1038/s41588‐024‐01687‐w10.1038/s41588‐024‐01687‐w ↗